Işın ÜREYEN, MUSTAFA ALPER KARALÖK, Deniz HIZLI, YUSUF AYTAÇ TOHMA, Ömer TAPISIZ, AHMET TANER TURAN, Nurettin BORAN, Gökhan TULUNAY, M. Faruk KÖSE

First-line adjuvan paklitaksel/karboplatin kemoterapisi alan hasta grubunda yaşın hematolojik toksisite üzerine etkisi

Giriş: First-line paklitaksel/karboplatin kombinasyonu-nun neden olduğu hematolojik toksisite üzerine yaşın etkisi araştırıldı. Materyal ve Metot: Jinekolojik malignite nedeniyle opere edilmiş ve first-line olarak paklitaksel/karboplatin kemoterapisi verilmiş 263 hastaya ait toksisite verileri retrospektif olarak değerlendirildi. Kemoterapiye 175 mg/m² dozunda paklitakselle başlandı. Takiben AUC= 6’dan hesaplanan karboplatin verildi. Tedavi 21 gün arayla uygulandı. Toksisite Dünya Sağlık Örgütü kriterlerine göre değerlendirildi. Bulgular: Ortalama yaş 53,6 yıl olup, 52 hastanın yaşı 65 ve üzerindeydi. Hastaların %75,7’sinde trombositopeni, %17,1’inde anemi ve %9,1’inde lökopeni gelişmedi. Pri-mer odak ve evre hematolojik toksisiteyle ilişkili değildi. Genç grupta hastaların %19,9’unda anemi gözlenmez-ken, bu oran yaşlı grupta %5,8’di. Lökopenide bu oranlar sırasıyla %10 ve %5,8’ti. Ancak bu farklılıklar istatis-tiksel olarak anlamsızdı (sırasıyla p=0,103, p=0,124). İki grup gelişen trombositopeni oranı ve toksisitenin ciddiyeti açısından birbirine oldukça benzerdi. Tartışma: Bu çalışmanın sonuçlarına göre, paklitaksel/ karboplatin kemoterapisine bağlı olarak gelişen hema-tolojik toksisiteyle yaş arasında anlamlı bir ilişki yoktur. Ancak kemoterapi toksisitesinin yaşla ilişkisini anlaya-bilmek için iyi tasarlanmış çalışmalara ihtiyaç vardır.

Anahtar Kelimeler:

Geriyedönük çalışma, Kemoterapi, adjuvan, Yaş dağılımı, İlaç toksisitesi, Karboplatin, Paklitaksel

The effect of age on the hematologic toxicity in a patient population taking adjuvant paclitaxel and carboplatin as first-line chemotherapy

The effect of age on hematologic toxicity caused by the combination of paclitaxel and carboplatin as first-line chemotherapy is investigated. Material and Method: The toxicity data of the 263 patients who were operated for gynecological malignancy and treated with paclitaxel/carboplatin as first-line chemotherapy was analyzed retrospectively. 175 mg/m² dose of paclitaxel was started first, afterwards carboplatin the dose of which was calculated with an AUC=6 was given. These sessions were performed every 21 days. Toxicity was evaluated according to World Health Organization criteria. Results: The mean age was 53.6 years, 52 patients’ ages were 65 or older. Thrombocytopenia, anemia and leukopenia were not observed in 75.7%, 17.1% and 9.1% of patients respectively. Primary site and stage were not correlated with the toxicity. Anemia was not observed in 19.9% of the young patient group, while this ratio was 5.8% in the older population. These ratios were 10% and 5.8% respectively for leukopenia. However, these differences were not statistically significant (respectively, p=0.103, p=0.124). The ratio of throm-bocytopenia was quite similar in both groups. Discussion: According to the results of this study, there is no significant correlation between the hematologic toxicity caused by paclitaxel/carboplatin chemotherapy and age. Well-designed studies are required to clarify the relationship between the toxicity of chemotherapy and age.

Keywords:

Retrospective Studies, Chemotherapy, Adjuvant, Age Distribution, Drug Toxicity, Carboplatin, Paclitaxel,

PDF

___

1. Bookman M. Principles of chemotherapy in gynecologic cancer. In: Principles and Practice of Gynecologic Oncology. Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randal ME (eds). 4th edition 2005, Philadelphia, p: 461-87.
2. Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, et al. Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials, J Thorac Oncol 2006;1(6):556-63.
3. Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16(7):2352-8.
4. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience, J Clin Oncol 2007;25 (24):3699-704.
5. Gelman RS, Taylor SG 4th. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2(12):1404-13.
6. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, et al. Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer, J Clin Oncol 2005;23(4):850-6.
7. Chen H, Cantor A, Meyer J, Beth Corcoran M, Grendys E, Cavanaugh D, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003;97(4):1107-14.
8. du Bois A, Lück HJ, Bauknecht T, Möbus V, Bochtler H, Diergarten K, et al. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 1997;8(4):355-61.
9. WHO handbook for reporting results of cancer treatment. WHO Offset Publication 1979, No: 148 (http://whqlibdoc.who.int/offset/WHO_ OFFSET_48.pdf)
10. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, Vilas-Zornoza A, Jose-Eneriz ES, Garate L, et al. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukemia. Eur E Cancer 2007;43:2736-46.
11. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, Defelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2011 Nov 9.